Pharma: Stocks To Buy 2017

: Delivered a 516% return as it dominated its niche in the metabolic disease market.

: Gained 103% , evolving from a rare-disease specialist into a large-cap biotech giant. Blue-Chip & Dividend Leaders

While 2017 was a banner year, several headwinds shaped investment strategies: Pharm Exec's Top 50 Companies 2017 | PharmExec

: Led the industry in R&D spending, focused heavily on its blockbuster immunotherapy Keytruda .